Cancer%20Immunotherapy
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024-04-18;12(4): doi: 10.1136/jitc-2023-008378. PubMed PMID: 38641350; PMCID: PMC11029323.
Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024-04-16;15(1):2863. doi: 10.1038/s41467-024-46906-4. PubMed PMID: 38627362; PMCID: PMC11021475.
Nasrollahi E, Davar D. Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer. Cancer Immunol Res. 2024-04-02;OF1-OF2. doi: 10.1158/2326-6066.CIR-23-1091. PubMed PMID: 38373149.
Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carrol BT, Theuner J, Li S, Fu P, Kirkwood JM. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024-03-28; doi: 10.1001/jamaoncol.2023.7333. PubMed PMID: 38546551; PMCID: PMC10979364.
Maleki Vareki S, Davar D. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nat Rev Clin Oncol. 2024-03-20; doi: 10.1038/s41571-024-00882-2. PubMed PMID: 38509333.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024-03-07;JCO2302355. doi: 10.1200/JCO.23.02355. PubMed PMID: 38452313.
Vignali PDA, Luke JJ. Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clin Cancer Res. 2024-02-19; doi: 10.1158/1078-0432.CCR-23-3736. PubMed PMID: 38372597.
Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G. Glioblastoma vaccines: past, present, and opportunities. EBioMedicine. 2024-02-01;100104963. doi: 10.1016/j.ebiom.2023.104963. PubMed PMID: 38183840; PMCID: PMC10808938.
Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024-01-23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. PubMed PMID: 38113141.
Silk AW, Davar D. Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-17;OF1-OF3. doi: 10.1158/1078-0432.CCR-23-3320. PubMed PMID: 38230965.
Wu RC, Luke JJ. Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clin Cancer Res. 2024-01-05; doi: 10.1158/1078-0432.CCR-23-2437. PubMed PMID: 37870487; PMCID: PMC10842335.
Silk AW, Davar D. Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-03; doi: 10.1158/1078-0432.CCR-23-3320. PubMed PMID: 38170200.
Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024-01-02; doi: 10.1146/annurev-immunol-090222-110914. PubMed PMID: 38166256.
Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2023-12-06; doi: 10.1038/s41577-023-00973-8. PubMed PMID: 38057451.
Karapetyan L, Iheagwara UK, Olson AC, Chmura SJ, Skinner HK, Luke JJ. Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst. 2023-11-08; doi: 10.1093/jnci/djad118. PubMed PMID: 37348864; PMCID: PMC10637035.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02583-2. PubMed PMID: 37845511; PMCID: PMC10667090.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02593-0. PubMed PMID: 37857711; PMCID: PMC10667103.
Betof Warner A, Luke JJ. CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clin Cancer Res. 2023-10-02; doi: 10.1158/1078-0432.CCR-23-1333. PubMed PMID: 37534980; PMCID: PMC10592266.
Shan F, Cillo AR, Cardello C, Yuan DY, Kunning SR, Cui J, Lampenfeld C, Williams AM, McDonough AP, Pennathur A, Luketich JD, Kirkwood JM, Ferris RL, Bruno TC, Workman CJ, Benos PV, Vignali DAA. Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells. Sci Immunol. 2023-09-15;8(87):eadf6717. doi: 10.1126/sciimmunol.adf6717. PubMed PMID: 37713508.
Zhang X, Ferris L, Faries MB, Luke JJ. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023-09-10;JCO2300255. doi: 10.1200/JCO.23.00255. PubMed PMID: 37410978; PMCID: PMC10852382.
Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023-09-01;24(9):1415-1422. doi: 10.1038/s41590-023-01569-z. PubMed PMID: 37488429.
Augustin RC, Luke JJ. PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? Clin Cancer Res. 2023-09-01;29(17):3253-3255. doi: 10.1158/1078-0432.CCR-23-1194. PubMed PMID: 37378689; PMCID: PMC10527539.
Smithy JW, Luke JJ. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res. 2023-07-05;29(13):2345-2347. doi: 10.1158/1078-0432.CCR-23-0490. PubMed PMID: 37097465; PMCID: PMC10330271.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023-07-05;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. PubMed PMID: 37227176.
Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023-06-01;5(6):e360-e369. doi: 10.1016/S2589-7500(23)00046-8. PubMed PMID: 37087370; PMCID: PMC10245380.
Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023-05-15;133(10): doi: 10.1172/JCI162260. PubMed PMID: 37183819; PMCID: PMC10178837.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss JF, Hava DL, Janku F. Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023-05-09; doi: 10.1158/1078-0432.CCR-23-0118. PubMed PMID: 37159185.
Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023-05-01;159(5):545-553. doi: 10.1001/jamadermatol.2023.0127. PubMed PMID: 36920356.
Gocher-Demske AM, Cui J, Szymczak-Workman AL, Vignali KM, Latini JN, Pieklo GP, Kimball JC, Avery L, Cipolla EM, Huckestein BR, Hedden L, Meisel M, Alcorn JF, Kane LP, Workman CJ, Vignali DAA. IFNγ-induction of T(H)1-like regulatory T cells controls antiviral responses. Nat Immunol. 2023-05-01;24(5):841-854. doi: 10.1038/s41590-023-01453-w. PubMed PMID: 36928412; PMCID: PMC10224582.
Olson DJ, Luke JJ. Myeloid Maturity: ATRA to Enhance Anti-PD-1? Clin Cancer Res. 2023-04-03;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652. PubMed PMID: 36656164; PMCID: PMC10073251.
Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, Oesterreich S, Vignali DAA. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer. 2023-04-01;4(4):516-534. doi: 10.1038/s43018-023-00527-w. PubMed PMID: 36927792.
Karapetyan L, Luke JJ. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clin Cancer Res. 2023-03-01;29(5):835-837. doi: 10.1158/1078-0432.CCR-22-3312. PubMed PMID: 36534010; PMCID: PMC9992241.
Sacirbegovic F, Günther M, Greco A, Zhao D, Wang X, Zhou M, Rosenberger S, Oberbarnscheidt MH, Held W, McNiff J, Jain D, Höfer T, Shlomchik WD. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023-02-14;56(2):369-385.e6. doi: 10.1016/j.immuni.2023.01.003. PubMed PMID: 36720219; PMCID: PMC10182785.
Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, Schroeder A, Bourhis J. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rev. 2023-02-01;113102492. doi: 10.1016/j.ctrv.2022.102492. PubMed PMID: 36640618.
Augustin RC, Bao R, Luke JJ. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clin Cancer Res. 2023-02-01;29(3):505-507. doi: 10.1158/1078-0432.CCR-22-3022. PubMed PMID: 36383142; PMCID: PMC9898080.
Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023-02-01;11(2): doi: 10.1136/jitc-2022-006007. PubMed PMID: 36750253; PMCID: PMC9906388.
Whiteside T, Zarour HM. In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J Immunother Cancer. 2023-01-30;11(1): doi: 10.1136/jitc-2023-006761. PubMed PMID: 36717185; PMCID: PMC9887713.
Ferris RL, Westra W. Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma. Annu Rev Pathol. 2023-01-24;18515-535. doi: 10.1146/annurev-pathmechdis-031521-041424. PubMed PMID: 36693202.
Augustin RC, Luke JJ. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol. 2023-01-20;41(3):443-446. doi: 10.1200/JCO.22.01770. PubMed PMID: 36162010; PMCID: PMC9870232.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023-01-20;41(3):425-435. doi: 10.1200/JCO.22.02264. PubMed PMID: 36649675.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023-01-10;41(2):186-197. doi: 10.1200/JCO.22.01763. PubMed PMID: 36166727; PMCID: PMC9839305.
Zarour HM. Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. Cell Metab. 2022-12-06;34(12):1903-1905. doi: 10.1016/j.cmet.2022.11.010. PubMed PMID: 36476933.
Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022-12-01;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390. PubMed PMID: 35579997; PMCID: PMC9669281.
Anagnostou V, Luke JJ. Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. Clin Cancer Res. 2022-11-14;28(22):4835-4837. doi: 10.1158/1078-0432.CCR-22-2277. PubMed PMID: 36103258; PMCID: PMC9669208.
Puthanmadhom Narayanan S, Najjar YG. Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? JAMA Oncol. 2022-11-01;8(11):1698-1699. doi: 10.1001/jamaoncol.2022.3776. PubMed PMID: 36048458.
Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022-11-01;8(11):944-961. doi: 10.1016/j.trecan.2022.06.008. PubMed PMID: 35853825; PMCID: PMC9588644.
Davar D, Zarour HM. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res. 2022-10-14;28(20):4370-4384. doi: 10.1158/1078-0432.CCR-21-1129. PubMed PMID: 35748749; PMCID: PMC9561605.
Shaikh SS, Yang X, Fortman DD, Wang H, Davar D, Luke JJ, Zarour H, Kirkwood JM, Najjar YG. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022-10-01;87(4):906-908. doi: 10.1016/j.jaad.2022.05.008. PubMed PMID: 35551967; PMCID: PMC9085439.
Hassel JC, Luke JJ. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clin Cancer Res. 2022-09-15;28(18):3914-3916. doi: 10.1158/1078-0432.CCR-22-1664. PubMed PMID: 36106401; PMCID: PMC9494631.
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022-09-15;28(18):3990-4002. doi: 10.1158/1078-0432.CCR-22-0339. PubMed PMID: 35499569; PMCID: PMC9475244.
Luke JJ, Ibrahim N, Eggermont AM. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply. Lancet. 2022-08-20;400(10352):559-560. doi: 10.1016/S0140-6736(22)01350-2. PubMed PMID: 35988561.
Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022-08-01;10(8): doi: 10.1136/jitc-2022-005036. PubMed PMID: 35973745; PMCID: PMC9386211.
Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022-07-01;19(7):431-439. doi: 10.1038/s41571-022-00630-4. PubMed PMID: 35468949.
Somasundaram A, Cillo AR, Lampenfeld C, Workman CJ, Kunning S, Oliveri L, Velez M, Joyce S, Calderon M, Dadey R, Rajasundaram D, Normolle DP, Watkins SC, Herman JG, Kirkwood JM, Lipson EJ, Ferris RL, Bruno TC, Vignali DAA. Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. Cancer Immunol Res. 2022-07-01;10(7):885-899. doi: 10.1158/2326-6066.CIR-20-0736. PubMed PMID: 35587532; PMCID: PMC10286228.
Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, Lafyatis R, Wherry EJ, Das J, Workman CJ, Vignali DAA. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022-06-01;23(6):868-877. doi: 10.1038/s41590-022-01210-5. PubMed PMID: 35618829; PMCID: PMC9179227.
Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest. 2022-05-02;132(9): doi: 10.1172/JCI152864. PubMed PMID: 35316223; PMCID: PMC9057587.
Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022-05-01;23(5):757-767. doi: 10.1038/s41590-022-01176-4. PubMed PMID: 35437325; PMCID: PMC9106921.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022-04-30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. PubMed PMID: 35367007.
Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022-04-10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. PubMed PMID: 35007144; PMCID: PMC8987226.
Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA, Duvvuri U, Johnson JT, Petro D, Heron DE, Clump DA, Bruno TC, Bauman JE. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022-04-01;28(7):1335-1344. doi: 10.1158/1078-0432.CCR-21-0426. PubMed PMID: 35091445; PMCID: PMC9164766.
Ferris RL, Burtness B, Flamand Y. Reply to A.S. Garden. J Clin Oncol. 2022-04-01;40(10):1133-1134. doi: 10.1200/JCO.22.00063. PubMed PMID: 35171688.
Grebinoski S, Gocher-Demske AM, Vignali DAA. Catch and release: freeing up PD-L1 ameliorates autoimmunity. Nat Immunol. 2022-03-01;23(3):344-346. doi: 10.1038/s41590-022-01140-2. PubMed PMID: 35190718; PMCID: PMC9809504.
Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022-03-01;22(3):158-172. doi: 10.1038/s41577-021-00566-3. PubMed PMID: 34155388; PMCID: PMC8688586.
Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022-02-15;28(4):677-688. doi: 10.1158/1078-0432.CCR-21-1963. PubMed PMID: 34716197.
Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022-02-01;10(2): doi: 10.1136/jitc-2021-004089. PubMed PMID: 35135866; PMCID: PMC8830302.
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022-01-10;40(2):138-149. doi: 10.1200/JCO.21.01752. PubMed PMID: 34699271; PMCID: PMC8718241.
Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022-01-01;10(1): doi: 10.1136/jitc-2021-004310. PubMed PMID: 35074904; PMCID: PMC8788316.
Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022-01-01;3(1):11-24. doi: 10.1038/s43018-021-00319-0. PubMed PMID: 35121998.
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021-12-17;12(1):7338. doi: 10.1038/s41467-021-27619-4. PubMed PMID: 34921143; PMCID: PMC8683505.
Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Buckanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med. 2021-12-08;13(623):eabf8495. doi: 10.1126/scitranslmed.abf8495. PubMed PMID: 34878821; PMCID: PMC9022491.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Nguyen-Duc A, Viale G, Molinero L, Emens LA. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021-11-29;113(12):1733-1743. doi: 10.1093/jnci/djab108. PubMed PMID: 34097070; PMCID: PMC8634452.
Emens LA. Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. J Natl Cancer Inst. 2021-11-29;113(12):1601-1603. doi: 10.1093/jnci/djab068. PubMed PMID: 33823004; PMCID: PMC8634411.
Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021-11-01;9(11): doi: 10.1136/jitc-2021-003675. PubMed PMID: 34782430; PMCID: PMC8593702.
Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021-10-15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. PubMed PMID: 34168049.
Andrews LP, Vignali KM, Szymczak-Workman AL, Burton AR, Brunazzi EA, Ngiow SF, Harusato A, Sharpe AH, Wherry EJ, Taniuchi I, Workman CJ, Vignali DAA. A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity. 2021-10-12;54(10):2209-2217.e6. doi: 10.1016/j.immuni.2021.08.029. PubMed PMID: 34551314.
Jameson-Lee M, Luke JJ. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021-10-01;27(19):5153-5155. doi: 10.1158/1078-0432.CCR-21-2406. PubMed PMID: 34341015; PMCID: PMC8807780.
Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D, Anderson CJ, Edwards WB, Kohanbash G. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. EBioMedicine. 2021-09-01;71103571. doi: 10.1016/j.ebiom.2021.103571. PubMed PMID: 34530385; PMCID: PMC8446777.
Yang X, Karapetyan L, Kirkwood JM. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Ann Intern Med. 2021-09-01;174(9):1345. doi: 10.7326/L21-0441. PubMed PMID: 34543597.
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021-08-20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. PubMed PMID: 33945288; PMCID: PMC8376314.
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021-08-02;113(8):1005-1016. doi: 10.1093/jnci/djab004. PubMed PMID: 33523233; PMCID: PMC8328980.
Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021-08-01;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. PubMed PMID: 33753453; PMCID: PMC8338751.
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021-08-01;9(8): doi: 10.1136/jitc-2021-002597. PubMed PMID: 34389617; PMCID: PMC8365813.
Najjar YG. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-002820. PubMed PMID: 34312244; PMCID: PMC8314703.
Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021-06-01;9(6): doi: 10.1136/jitc-2021-002568. PubMed PMID: 34083421; PMCID: PMC8183204.
Lai SY, Ferris RL. Reply to N. Hirshoren et al and D. Chakrabarti et al. J Clin Oncol. 2021-05-10;39(14):1600-1601. doi: 10.1200/JCO.21.00027. PubMed PMID: 33705206.
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2021-002535. PubMed PMID: 33963015; PMCID: PMC8108687.
Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2020-002088. PubMed PMID: 33986123; PMCID: PMC8126285.
Korkmaz E, Balmert SC, Sumpter TL, Carey CD, Erdos G, Falo LD Jr. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev. 2021-04-01;171164-186. doi: 10.1016/j.addr.2021.01.022. PubMed PMID: 33539853; PMCID: PMC8060128.
Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz MB, Dubner HM, Ernst SJ, Rose A, Najjar YG, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021-02-05;371(6529):595-602. doi: 10.1126/science.abf3363. PubMed PMID: 33542131; PMCID: PMC8097968.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021-02-01;9(2): doi: 10.1136/jitc-2020-002015. PubMed PMID: 33608377; PMCID: PMC7898862.
Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021-01-04;218(1): doi: 10.1084/jem.20192179. PubMed PMID: 33601411; PMCID: PMC7754677.
Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020-12-15;26(24):6437-6444. doi: 10.1158/1078-0432.CCR-20-1790. PubMed PMID: 33028595; PMCID: PMC8561652.
Rohatgi A, Kirkwood JM. Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020-12-01;17(12):721-722. doi: 10.1038/s41571-020-00437-1. PubMed PMID: 32978607.
Lai SY, Ferris RL. Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. J Clin Oncol. 2020-12-01;38(34):3983-3986. doi: 10.1200/JCO.20.02716. PubMed PMID: 33052758.
Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020-10-27;12(1):90. doi: 10.1186/s13073-020-00787-6. PubMed PMID: 33106165; PMCID: PMC7590690.
Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020-10-15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. PubMed PMID: 32591463; PMCID: PMC8045409.
Falo LD Jr. Advances in skin science enable the development of a COVID-19 vaccine. J Am Acad Dermatol. 2020-10-01;83(4):1226-1227. doi: 10.1016/j.jaad.2020.05.126. PubMed PMID: 32485211; PMCID: PMC7260504.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020-10-01;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. PubMed PMID: 33002436.
Subbiah V, Baik C, Kirkwood JM. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020-09-01;6(9):797-810. doi: 10.1016/j.trecan.2020.05.009. PubMed PMID: 32540454.
Liu C, Somasundaram A, Manne S, Gocher AM, Szymczak-Workman AL, Vignali KM, Scott EN, Normolle DP, John Wherry E, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020-09-01;21(9):1010-1021. doi: 10.1038/s41590-020-0733-2. PubMed PMID: 32661362; PMCID: PMC7442600.
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020-09-01;8(2): doi: 10.1136/jitc-2020-000957. PubMed PMID: 32900861; PMCID: PMC7477968.
Zhou M, Sacirbegovic F, Zhao K, Rosenberger S, Shlomchik WD. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020-08-24;11(1):4227. doi: 10.1038/s41467-020-17991-y. PubMed PMID: 32839441; PMCID: PMC7445289.
Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020-08-15;26(16):4171-4173. doi: 10.1158/1078-0432.CCR-20-1558. PubMed PMID: 32487680; PMCID: PMC7442612.
Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020-08-01;26(15):3901-3907. doi: 10.1158/1078-0432.CCR-19-1321. PubMed PMID: 32332013; PMCID: PMC7607412.
Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, Lin H, Normolle DP, Moynihan KD, Taniuchi I, Irvine DJ, Kirkwood JM, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020-07-17;5(49): doi: 10.1126/sciimmunol.abc2728. PubMed PMID: 32680952; PMCID: PMC7901539.
Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-001020. PubMed PMID: 32675312; PMCID: PMC7372174.
Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-000967. PubMed PMID: 32675311; PMCID: PMC7368550.
Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020-06-01;8(1): doi: 10.1136/jitc-2019-000331. PubMed PMID: 32581057; PMCID: PMC7319717.
Ding QQ, Chauvin JM, Zarour HM. Targeting novel inhibitory receptors in cancer immunotherapy. Semin Immunol. 2020-06-01;49101436. doi: 10.1016/j.smim.2020.101436. PubMed PMID: 33288379; PMCID: PMC8045408.
Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020-04-01;17(4):198-199. doi: 10.1038/s41571-020-0328-8. PubMed PMID: 31974501.
Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020-03-01;84101947. doi: 10.1016/j.ctrv.2019.101947. PubMed PMID: 31926403.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020-02-20;38(6):567-575. doi: 10.1200/JCO.19.01381. PubMed PMID: 31880964; PMCID: PMC7030886.
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020-02-15;26(4):804-811. doi: 10.1158/1078-0432.CCR-19-1223. PubMed PMID: 31558480; PMCID: PMC7055933.
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020-01-14;52(1):183-199.e9. doi: 10.1016/j.immuni.2019.11.014. PubMed PMID: 31924475; PMCID: PMC7201194.
Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet. 2019-11-23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5. PubMed PMID: 31679948.
Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019-11-01;20(11):1425-1434. doi: 10.1038/s41590-019-0512-0. PubMed PMID: 31611702.
Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019-11-01;16(11):669-683. doi: 10.1038/s41571-019-0227-z. PubMed PMID: 31189965.
Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019-10-23;7(1):274. doi: 10.1186/s40425-019-0740-8. PubMed PMID: 31647026; PMCID: PMC6813065.
Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019-09-01;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. PubMed PMID: 31239321; PMCID: PMC7721346.
Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, Lafyatis RA, Chen W, Delgoffe GM, Workman CJ, Wendell SG, Vignali DAA. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-γ. Immunity. 2019-08-20;51(2):381-397.e6. doi: 10.1016/j.immuni.2019.06.017. PubMed PMID: 31350177; PMCID: PMC6703933.
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019-07-15;7(1):184. doi: 10.1186/s40425-019-0662-5. PubMed PMID: 31307547; PMCID: PMC6632213.
Ferris RL, Cramer JD, Branstetter Iv BF. Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2019-07-10;37(20):1683-1685. doi: 10.1200/JCO.19.00544. PubMed PMID: 31150317; PMCID: PMC6638595.
Davar D, Kirkwood JM. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019-07-01;5(7):942-943. doi: 10.1001/jamaoncol.2019.0413. PubMed PMID: 31021377.
Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019-06-01;20(6):724-735. doi: 10.1038/s41590-019-0346-9. PubMed PMID: 30936494; PMCID: PMC6531353.
Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019-04-24;7(1):113. doi: 10.1186/s40425-019-0552-x. PubMed PMID: 31014399; PMCID: PMC6480917.
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019-04-01;42101305. doi: 10.1016/j.smim.2019.101305. PubMed PMID: 31604537; PMCID: PMC6920665.
Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019-03-07;380(10):987-988. doi: 10.1056/NEJMc1900150. PubMed PMID: 30855757.
Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res. 2019-01-15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. PubMed PMID: 30420448; PMCID: PMC6335150.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019-01-01;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. PubMed PMID: 30242306; PMCID: PMC6439773.
Fakhry C, Ferris RL. P16 as a Prognostic Biomarker for Nonoropharyngeal Squamous Cell Cancers: Avatar or Mirage? J Natl Cancer Inst. 2018-12-01;110(12):1290-1291. doi: 10.1093/jnci/djy103. PubMed PMID: 29878233.
Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients. Cancer Immunol Res. 2018-12-01;6(12):1548-1560. doi: 10.1158/2326-6066.CIR-18-0062. PubMed PMID: 30282672; PMCID: PMC6512340.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018-11-01;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. PubMed PMID: 29931076; PMCID: PMC6248084.
Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018-10-25;36(35):JCO1800632. doi: 10.1200/JCO.18.00632. PubMed PMID: 30359157; PMCID: PMC6286160.
Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018-10-23;6(1):112. doi: 10.1186/s40425-018-0428-5. PubMed PMID: 30352626; PMCID: PMC6199801.
Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018-09-15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. PubMed PMID: 29712685; PMCID: PMC6139056.
Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018-08-31;6(1):83. doi: 10.1186/s40425-018-0393-z. PubMed PMID: 30170622; PMCID: PMC6117978.
Overacre-Delgoffe AE, Vignali DAA. Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res. 2018-08-01;6(8):882-887. doi: 10.1158/2326-6066.CIR-18-0066. PubMed PMID: 30068755; PMCID: PMC6080214.
Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018-07-01;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. PubMed PMID: 29908991.
Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA. Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. J Natl Cancer Inst. 2018-07-01;110(7):696-698. doi: 10.1093/jnci/djy014. PubMed PMID: 29471462.
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018-06-18;6(1):57. doi: 10.1186/s40425-018-0360-8. PubMed PMID: 29914571; PMCID: PMC6006764.
Long GV, Hauschild A, Kirkwood JM. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018-02-15;378(7):679-680. doi: 10.1056/NEJMc1716071. PubMed PMID: 29443674.
Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018-02-01;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. PubMed PMID: 28801472; PMCID: PMC5796849.
Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018-02-01;6348-60. doi: 10.1016/j.ctrv.2017.11.008. PubMed PMID: 29223828; PMCID: PMC7505164.
Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res. 2018-01-01;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. PubMed PMID: 29061643; PMCID: PMC5754237.
Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE. Report on the Third FDA-AACR Oncology Dose-Finding Workshop. Cancer Immunol Res. 2017-12-01;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590. PubMed PMID: 29196440.
Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017-11-15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. PubMed PMID: 28904066; PMCID: PMC5690836.
Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017-11-15;23(22):6888-6892. doi: 10.1158/1078-0432.CCR-17-1317. PubMed PMID: 28790109; PMCID: PMC5690823.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017-11-09;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. PubMed PMID: 28891408.
Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017-09-19;5(1):74. doi: 10.1186/s40425-017-0279-5. PubMed PMID: 28923120; PMCID: PMC5604296.
Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017-08-01;3(8):1112-1115. doi: 10.1001/jamaoncol.2016.6779. PubMed PMID: 28241191; PMCID: PMC5552417.
Matte-Martone C, Liu J, Zhou M, Chikina M, Green DR, Harty JT, Shlomchik WD. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity. J Clin Invest. 2017-06-30;127(7):2765-2776. doi: 10.1172/JCI85736. PubMed PMID: 28604385; PMCID: PMC5490746.
Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res. 2017-06-01;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. PubMed PMID: 28483787; PMCID: PMC5550830.
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, Vignali DAA. Interferon-γ Drives T(reg) Fragility to Promote Anti-tumor Immunity. Cell. 2017-06-01;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. PubMed PMID: 28552348; PMCID: PMC5509332.
Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1(+) and TIM-3(+) TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res. 2017-05-01;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. PubMed PMID: 28408386; PMCID: PMC5497750.
Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017-05-01;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. PubMed PMID: 27799249; PMCID: PMC5411325.
Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, Normolle D, Bettini M, Workman CJ, Vignali DAA. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol. 2017-03-31;2(9): doi: 10.1126/sciimmunol.aah4569. PubMed PMID: 28783703; PMCID: PMC5609824.
Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol. 2017-03-10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. PubMed PMID: 28135150; PMCID: PMC5455684.
Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017-03-01;276(1):80-96. doi: 10.1111/imr.12519. PubMed PMID: 28258692; PMCID: PMC5338468.
Ferris R, Gillison ML. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med. 2017-02-09;376(6):596. doi: 10.1056/NEJMc1615565. PubMed PMID: 28177863.
Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017-02-01;23(3):707-716. doi: 10.1158/1078-0432.CCR-16-0879. PubMed PMID: 27496866; PMCID: PMC5290200.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016-11-10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. PubMed PMID: 27718784; PMCID: PMC5564292.
Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res. 2016-11-01;22(21):5229-5237. doi: 10.1158/1078-0432.CCR-15-2971. PubMed PMID: 27217441; PMCID: PMC5093040.
Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol. 2016-10-01;18(10):1442-50. doi: 10.1093/neuonc/now038. PubMed PMID: 27006176; PMCID: PMC5035517.
Emens LA. It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer. 2016-08-16;443. doi: 10.1186/s40425-016-0147-8. PubMed PMID: 27532018; PMCID: PMC4986195.
Ferris RL, Galon J. Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification. J Natl Cancer Inst. 2016-08-01;108(8): doi: 10.1093/jnci/djw033. PubMed PMID: 27172904; PMCID: PMC5017936.
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016-08-01;18(8):1157-68. doi: 10.1093/neuonc/now026. PubMed PMID: 26984745; PMCID: PMC4933485.
Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016-07-19;442. doi: 10.1186/s40425-016-0146-9. PubMed PMID: 27437105; PMCID: PMC4949883.
Davar D, Fuchs SY, Kirkwood JM. BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016-07-01;108(7): doi: 10.1093/jnci/djv432. PubMed PMID: 26851801.
Zhang Q, Vignali DA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016-05-17;44(5):1034-51. doi: 10.1016/j.immuni.2016.04.017. PubMed PMID: 27192568; PMCID: PMC4873959.
Zarour HM. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res. 2016-04-15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849. PubMed PMID: 27084739; PMCID: PMC4872712.
Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016-03-01;76(5):1031-43. doi: 10.1158/0008-5472.CAN-15-2001. PubMed PMID: 26676749; PMCID: PMC4775348.
Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA. Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 2016-02-16;44(2):316-29. doi: 10.1016/j.immuni.2016.01.013. PubMed PMID: 26872697; PMCID: PMC4758699.
Davar D, Kirkwood JM. CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res. 2015-12-15;21(24):5412-4. doi: 10.1158/1078-0432.CCR-14-3132. PubMed PMID: 26672083; PMCID: PMC4683414.
Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl J Clin Oncol. 2015-12-01;33(34):4066-76. doi: 10.1200/JCO.2015.62.0500. PubMed PMID: 26351350; PMCID: PMC4669592.
Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015-11-17;354. doi: 10.1186/s40425-015-0097-6. PubMed PMID: 26579227; PMCID: PMC4647471.
Emens LA. Chemotherapy--A Viable Partner for Cancer Immunotherapy? JAMA Oncol. 2015-11-01;1(8):1095-7. doi: 10.1001/jamaoncol.2015.2733. PubMed PMID: 26291503.
Emens LA, Romero P. Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. J Immunother Cancer. 2015-10-20;349. doi: 10.1186/s40425-015-0092-y. PubMed PMID: 26500777; PMCID: PMC4617860.
Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015-10-10;33(29):3293-304. doi: 10.1200/JCO.2015.61.1509. PubMed PMID: 26351330; PMCID: PMC4586169.
Holsinger FC, Ferris RL. Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. J Clin Oncol. 2015-10-10;33(29):3285-92. doi: 10.1200/JCO.2015.62.3157. PubMed PMID: 26351337; PMCID: PMC4586168.
Bauman JE, Ferris RL. Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind. JAMA Oncol. 2015-10-01;1(7):915-7. doi: 10.1001/jamaoncol.2015.2606. PubMed PMID: 26226055.
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015-09-15;339. doi: 10.1186/s40425-015-0081-1. PubMed PMID: 26380086; PMCID: PMC4570556.
Korkmaz E, Friedrich EE, Ramadan MH, Erdos G, Mathers AR, Burak Ozdoganlar O, Washburn NR, Falo LD Jr. Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. Acta Biomater. 2015-09-01;2496-105. doi: 10.1016/j.actbio.2015.05.036. PubMed PMID: 26093066; PMCID: PMC8266287.
Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med. 2015-08-26;6791-101. doi: 10.1146/annurev-med-051914-021907. PubMed PMID: 26332002; PMCID: PMC5242186.
Goldman S, Bouffet E, Fisher PG, Allen JC, Robertson PL, Chuba PJ, Donahue B, Kretschmar CS, Zhou T, Buxton AB, Pollack IF. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. J Clin Oncol. 2015-08-01;33(22):2464-71. doi: 10.1200/JCO.2014.59.5132. PubMed PMID: 26101244; PMCID: PMC4507465.
Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF 4th, Ferrone S, Ferris RL. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res. 2015-08-01;3(8):936-45. doi: 10.1158/2326-6066.CIR-15-0053. PubMed PMID: 25972070; PMCID: PMC4526378.
Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res. 2015-06-01;75(11):2200-10. doi: 10.1158/0008-5472.CAN-14-2788. PubMed PMID: 25832655; PMCID: PMC4452385.
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015-05-01;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064. PubMed PMID: 25941355; PMCID: PMC5012642.
Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, Zarour HM. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015-04-15;75(8):1635-44. doi: 10.1158/0008-5472.CAN-14-3016. PubMed PMID: 25720800; PMCID: PMC4401638.
Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015-02-01;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. PubMed PMID: 25480946; PMCID: PMC4315704.
Sumpter TL, Falo LD Jr. "Toll"-erance in the skin. Immunity. 2014-11-20;41(5):677-9. doi: 10.1016/j.immuni.2014.11.003. PubMed PMID: 25517608.
Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014-11-05;312(17):1744-53. doi: 10.1001/jama.2014.13943. PubMed PMID: 25369488; PMCID: PMC4336189.
Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014-10-01;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. PubMed PMID: 25116755; PMCID: PMC4211036.
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and n J Clin Oncol. 2014-07-01;32(19):2050-8. doi: 10.1200/JCO.2013.54.0526. PubMed PMID: 24888813; PMCID: PMC4067943.
Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009-12-10;27(35):5911-8. doi: 10.1200/JCO.2009.23.3494. PubMed PMID: 19805669; PMCID: PMC2793039.
Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007-07-01;13(13):3951-9. doi: 10.1158/1078-0432.CCR-07-0374. PubMed PMID: 17606729.
Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005-12-01;65(23):11146-55. doi: 10.1158/0008-5472.CAN-05-0772. PubMed PMID: 16322265.
